W.E. Berdel - Concepedia

Author

W.E. Berdel

Freie Universität Berlin

Also Known As

K. Spiekermann, K.-M. Debatin, W Berdel, W E Berdel, W. Berdel, W. E. Berdel, W.E. Berdel, Wofgang E. Berdel

Publications

327

Citations

H-Index

Concepts

All Affiliations

Freie Universität Berlin Klinikum rechts der Isar Eppendorf (Germany)Humboldt-Universität zu Berlin University of Münster

About

W.E. Berdel is an author at Freie Universität Berlin specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	176
2	Health Sciences	4	4	101
3	Immunology	1	1	17
4	Medical Laboratory Science	1	1	16
5	Orthopaedics	1	1	10

W.E. Berdel

Publications

251

Citations

H-Index

Page 1

	Year	Citations
Phase I Clinical Trial of a Day-1, -3, -5 Every 3 WeeksPhase I Clinical Trial of Day-1, -3, -5 Every 3 Weeks Schedule with Titanocene Dichloride (MKT 5) in Patients with Advanced Cancer. (Phase I Study Group of the AIO of the German Cancer Society) K. Mross, P. Robben-Bathe, Lutz Edler, Oncology Research and Treatment Serum CreatinineTumor BiologyTitanocene DichlorideMedicineMetronomic Therapy	2000	54
The use of dose-intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumors. German Testicular Cancer Study Group. Carsten Bokemeyer, A. Harstrick, J. Beyer, PubMed	1998	47
Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion R. Thödtmann, Andreas Hüttmann, W.E. Berdel, Investigational New Drugs MedicineIntravenous Short InfusionClinical PharmacologyPharmacokinetic TrialPharmacotherapy	1998	33
A single-blind, randomised, vehicle-controlled dose-finding study of recombinant human granulocyte colony-stimulating factor (lenograstim) in patients undergoing chemotherapy for solid cancers and lymphoma Austin M. Seymour, Elisângela de Jesus Campos, Nicholas Thatcher, European Journal of Cancer Hematological MalignancySolid CancersMedicineMalignant Blood DisorderImmunology	1995	17
cis-platinum (DDP) and VP 16-213 (etoposide) combination chemotherapy for advanced non-small cell lung cancer. A phase II clinical trial P.S. Mitrou, M. Graubner, W.E. Berdel, European Journal of Cancer and Clinical Oncology Combination ChemotherapyMedicineMetronomic TherapyBronchial NeoplasmCancer Treatment	1984	17
Phase I Clinical and Pharmacokinetic Study of LU103793 (Cemadotin Hydrochloride) as an Intravenous Bolus Injection in Patients with Metastatic Solid Tumors K. Mross, Katrina Herbst, W.E. Berdel, Oncology Research and Treatment Cemadotin HydrochloridePharmacotherapyWhole Blood SamplesPre-clinical PharmacologyRadiopharmaceutical Therapy	1996	16
The German CML Study, Comparison of Busulfan vs. Hydroxyurea vs. Interferon alpha and Establishment of Prognostic Score 1 R. Hehlmann, H. Heimpel, H. J. Kolb, Leukemia & lymphoma/Leukemia and lymphoma Renal PathologyPrognosisPathologyInterferon AlphaGerman Cml Study	1993	16
Tumor Necrosis Factor in Advanced Colorectal Cancer: A Phase II Study Manfred Heim, R. Siegmund, H. J. Illiger, Oncology Research and Treatment	1990	15
Daily Oral Miltefosine (Hexadecyl-Phosphocholine) in Patients with Advanced Non-Small Cell Lung Cancer. A Phase II Study W.E. Berdel, R. Becher, Lutz Edler, Oncology Research and Treatment Oral MilAntifibrotic TherapyEligibility CriteriaCancer ManagementPathology	1992	13
Sequential Trimetrexate, 5-Fluorouracil and Folinic Acid Are Effective and Well Tolerated in Metastatic Colorectal Carcinoma Hubert Szelényi, Peter Hohenberger, Herbert Lochs, Oncology	2000	13

Page 1